Compare Chipotle Mexican Grill, Inc. (CMG) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Davita Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $36.5 (market cap $46.73B), while Davita Inc trades at $230.51 (market cap $14.92B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 3.1× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| CMG | DVA | |
|---|---|---|
Market Cap | $46.73B | $14.92B |
Sector | Consumer Cyclical | Health |
52-Week High | $53.95 | $235.71 |
52-Week Low | $28.17 | $103.87 |
Enterprise Value | $51.11B | $27.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $36.63, up 3.91% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $36 and resistance at $37-38. Recent earnings beats and international expansion into Mexico highlight growth potential, though valuation remains elevated with a P/E of 33.61. Analyst consensus is strongly bullish with 70% buy ratings and a $40.43 price target.
CMG offers growth exposure through international expansion and operational excellence, but faces risks from premium valuation and margin pressures. Revenue growth has slowed to 5.3% in 2025 from 15.1% in 2023, while net margins declined to 12.87%. The stock's premium multiple requires sustained execution to justify current levels amid competitive and inflationary pressures.
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
